Olanzapine or Lamotrigine Addition to Lithium in Remitted Bipolar Disorder Patients With Anxiety Disorder Comorbidity: A Randomized, Single-Blind, Pilot Study
J Clin Psychiatry 2008;69(4):609-616
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: The aim of the present randomized, single-blind,
pilot study was to assess the efficacy of the addition of a second mood
stabilizer, either olanzapine or lamotrigine, to lithium in patients with
remitted bipolar disorder and comorbid anxiety disorder.
Method: Adult DSM-IV bipolar disorder patients with a current
anxiety disorder and a Hamilton Rating Scale for Anxiety (HAM-A) score of 12 or
higher, in remission from an affective episode for at least 2 months while on
lithium maintenance treatment, were randomly assigned to receive 12 weeks of
single-blind olanzapine 5 to 10 mg/day (N = 24) or lamotrigine 50 to 200 mg/day
(N = 23) addition to lithium. The primary outcome measure was the HAM-A;
secondary outcome measures were the Clinical Global Impressions-Severity of
Illness scale and the Global Assessment of Functioning (GAF) scale. Data were
collected from July 2005 to February 2007.
Results: Twenty-two patients in the olanzapine and 18 in the
lamotrigine group completed the trial. Mean ± SD final doses of olanzapine and
lamotrigine were, respectively, 7.7 ± 4.2 mg/day and 96.7 ± 46.7 mg/day in the
intent-to-treat sample (N = 47). Both olanzapine and lamotrigine were effective
in reducing HAM-A scores from baseline to endpoint (paired t test for
completers: t = 11.361, df = 21, p < .001 for olanzapine and t = 6.301, df =
17, p < .001 for lamotrigine). Both drugs were also effective on the secondary
outcome measures. Olanzapine was more effective than lamotrigine at weeks 6 and
12 with a last-observation-carried-forward analysis on all 3 outcome measures,
while such differences disappeared on the HAM-A and GAF at week 12 with the
Conclusions: The addition of a second mood stabilizer (olanzapine
or lamotrigine) to lithium is effective in reducing anxiety symptoms in bipolar
disorder patients with a co-occurring anxiety disorder.